A pilot open label prospective study of memantine monotherapy in adults with ADHD

  title={A pilot open label prospective study of memantine monotherapy in adults with ADHD},
  author={Craig B. H. Surman and Paul G. Hammerness and Carter R. Petty and Thomas J. Spencer and Robert L. Doyle and Siena Napolean and Nicole Chu and Dayna M Yorks and Joseph Biederman},
  journal={The World Journal of Biological Psychiatry},
  pages={291 - 298}
Abstract Objectives. Available pharmacotherapies treat some adults with ADHD inadequately. A small literature suggests that glutamate modulation could have effects on ADHD. Methods. Memantine, an N‐methyl‐d‐aspartate (NMDA) receptor antagonist, was titrated to a maximum dose of 10 mg BID in 34 adult subjects aged 18–55 who met DSM-IV criteria for ADHD or ADHD NOS on structured interview. Twenty-eight subjects completed 12 weeks exposure. The Adult ADHD Investigator Symptom Report (AISRS… 
Memantine in the Treatment of Executive Function Deficits in Adults With ADHD
Among adults with ADHD and EFDs, adjunct treatment with memantine to osmotic release oral system-methylphenidate (OROS-MPH) was associated with improvements in selective areas of executive functioning, supporting the need for further research.
A Prospective Open-Label Trial of Memantine Hydrochloride for the Treatment of Social Deficits in Intellectually Capable Adults With Autism Spectrum Disorder
Treatment with memantine appears to be beneficial for the treatment of ASD and associated psychopathology and cognitive dysfunction in intellectually capable adults.
Memantine versus Methylphenidate in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Double-Blind, Randomized Clinical Trial
It was revealed that although memantine was less effective than methylphenidate in the treatment of attention deficit hyperactivity disorder, it may be considered as an alternative treatment.
Pilot Study of Droxidopa With Carbidopa in Adults With ADHD
Preliminary findings indicate that droxidopa can improve adult ADHD symptoms, and further studies are warranted to examine the efficacy and safety of droXidopa in ADHD.
Off-label use of memantine as adjunctive treatment in schizophrenia: a retrospective case series study.
Randomized controlled trials, wherein memantine is administered at adequate doses for an adequate period of time to ongoing antipsychotic treatment are required to confirm its efficacy in alleviating symptoms of schizophrenia.
Alternative pharmacological strategies for adult ADHD treatment: a systematic review
Among alternative compounds, amphetamines have the most robust evidence of efficacy, but they may be associated with serious side effects (e.g. psychotic symptoms or hypertension), and antidepressants, particularly those acting as noradrenaline or dopamine enhancers, have evidence of effective but should be avoided in patients with comorbid bipolar disorder.
Pharmacological treatment of adult ADHD
Effect sizes from the most recent studies are calculated and they are almost identical with prior estimates, and in terms of Cohen-d typically indicate medium-to-high effect sizes for the pharmacotherapy of adult ADHD.
Effects of methylphenidate on mismatch negativity and P3a amplitude of initially psychostimulant-naïve, adult ADHD patients.
No evidence for early information processing deficits in patients with ADHD, as measured with MMN and P3a amplitude is found, although more severe ADHD-symptoms were associated with larger MMN amplitudes in the patients.
Evaluation of the Efficacy of Memantine in Combination with Ritalin on the Severity of Hyperactivity and Attention Deficit Symptoms in Children
Although the symptoms severity of hyperactivity decreased, there was no significant difference between these two groups and the Ritalin might have had a significant effect on the symptoms reduction, and the Memantin added to Rital in did not have a special effect on reducing the severity of symptoms.
Emerging drugs for the treatment of attention-deficit hyperactivity disorder (ADHD)
A review of the scientific literature and of unpublished/ongoing clinical trials to summarize the advances made in the last 10 years for the pharmacological treatment of ADHD found many pharmacological mechanisms beyond dopaminergic and noradrenergic ones have been investigated in patients.


Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies
Effects of stimulant medication on neuropsychological functioning in young adults with attention-deficit/hyperactivity disorder.
This study showed that subjects with ADHD who took stimulant medication had higher neuropsychological measures of attention compared with subjects with attention-deficit/hyperactivity disorder who did not take stimulants, but differences were not found for other measures of executive function.
Neuropsychological function in adults with attention-deficit hyperactivity disorder
Neuropsychological Studies of Late Onset and Subthreshold Diagnoses of Adult Attention-Deficit/Hyperactivity Disorder
Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.
Available pharmacoeconomic data from Europe and the US, despite some inherent limitations, support the use of memantine as a cost-effective treatment in this patient population, although definitive conclusions are not feasible because of limited data.
Attention-deficit/hyperactivity disorder (adhd) as a noradrenergic disorder
Attention-deficit/hyperactivity disorder in adults: an overview
Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder.
  • J. FayyadR. de Graaf R. Jin
  • Medicine, Psychology
    The British journal of psychiatry : the journal of mental science
  • 2007
Estimates of ADHD prevalence and correlates in the World Health Organization World Mental Health Survey Initiative should be considered more seriously in future epidemiological and clinical studies than is currently the case.
Stimulants: Therapeutic Actions in ADHD
  • A. Arnsten
  • Biology, Psychology
  • 2006
Berridge et al have now shown that these low doses of methylphenidate produce marked increases in norepinephrine and dopamine release in the prefrontal cortex, whereas having only subtle effects on subcortical catecholamine release.